Capricor Therapeutics Inc. (CAPR), which recently received a setback from the FDA regarding its cell therapy for Duchenne muscular dystrophy, remains confident in its potential and is looking to the upcoming HOPE-3 trial results to support its regulatory progress.
The investigational treatment in focus, Deramiocel (CAP-1002), is made from allogeneic cardiosphere-derived cells (CDCs), a rare type of heart cell that has shown strong anti-inflammatory and anti-fibrotic effects in both preclinical and clinical studies. These effects help protect heart and muscle function in conditions like Duchenne muscular dystrophy.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.